Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant
Stopped early · Phase 1/Phase 2 · Has a placebo group
Conditions studied: Respiratory Tract Viral Infections, Human Metapneumovirus (hMPV) Infection, Parainfluenza (PIV) Infection, Respiratory Syncytial Viral (RSV) Infection, Influenza Infection
In brief
A study to evaluate ALVR106; an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets four community acquired respiratory viruses: respiratory syncytial virus (RSV), influenza, human metapneumovirus (hMPV), and/or parainfluenza virus (PIV) following hematopoietic cell transplant (HCT) and solid organ transplant (SOT).
Key facts
- Study ID
- NCT04933968
- Run by
- AlloVir
- People needed
- 17
- Starts
- 2022-03-21
- Expected to finish
- 2024-01-31
- Last updated by the study team
- 2024-06-06
Who can join
Age: 17 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Undergone hematopoietic cell transplantation (HCT) ≥21 days or solid organ transplantation (SOT) ≥28 days prior to study treatment administration
- Detection of at least 1 target virus of interest (ie, RSV, influenza, hMPV, and/or PIV)
- Diagnosis of Upper or mild Lower Respiratory Tract Infection
You may not qualify if…
- Ongoing therapy with high-dose systemic corticosteroids (ie, prednisone equivalent dose >0.5 mg/kg/day)
- Infection by novel coronavirus disease 2019 (COVID-19)
- For HCT patients, evidence of Grade >2 GVHD; and for SOT patients, any history or evidence of GVHD
Where it is running
- Scottsdale Healthcare Hospitals DBA HonorHealth — Scottsdale, Arizona, United States
- City of Hope — Duarte, California, United States
- University of Florida - Division of Hematology & Oncology — Gainesville, Florida, United States
- University of Miami - Sylvester Cancer Center — Miami, Florida, United States
- Northside Hospital — Atlanta, Georgia, United States
- University of Iowa — Iowa City, Iowa, United States
- University of Kansas Cancer Center — Kansas City, Kansas, United States
- Dana Farber Cancer Institute — Boston, Massachusetts, United States
- Roswell Park Comprehensive Cancer Center — Buffalo, New York, United States
- University of North Carolina - Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina, United States
- Duke University Medical Center — Durham, North Carolina, United States
- Wake Forest — Winston-Salem, North Carolina, United States
- The Cleveland Clinic Foundation — Cleveland, Ohio, United States
- Medical University of South Carolina — Charleston, South Carolina, United States
- Vanderbilt University Cancer Center — Nashville, Tennessee, United States
- Baylor College of Medicine — Houston, Texas, United States
- MD Anderson Cancer Center — Houston, Texas, United States
- MD Anderson — Houston, Texas, United States
- Virginia Commonwealth University — Richmond, Virginia, United States
- Fred Hutchinson Cancer Research Center — Seattle, Washington, United States
- Froedtert Hospital and the Medical College of Wisconsin — Milwaukee, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.